24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825

Post-Traumatic Stress Disorder
Resources
Basic Information
Introduction to Trauma and Stressor-Related DisordersSigns and Symptoms of Trauma and Stressor-Related DisordersDiagnostic Descriptions of Trauma and Stressor-Related DisordersWhat Causes the Symptoms of Trauma-Related Disorders? Treatment of Trauma, PTSD, Abuse and Other Stressor-Related Disorders Conclusion, Resources and ReferencesDealing with the Effects of Trauma - A Self-Help Guide
More InformationLatest NewsQuestions and AnswersLinks
Related Topics

Anxiety Disorders
Depression: Depression & Related Conditions
Addictions: Alcohol and Substance Abuse
Dissociative Disorders

SGA Prescribing Higher for Veterans With PTSD/Dementia


HealthDay News
Updated: Apr 7th 2017

new article illustration

FRIDAY, April 7, 2017 (HealthDay News) -- Elderly veterans with post-traumatic stress disorder (PTSD) with dementia have increased odds of being prescribed second-generation antipsychotics (SGAs) compared with those with PTSD alone, according to a study published online April 3 in the Journal of the American Geriatrics Society.

Todd P. Semla, Pharm.D., from the Department of Veterans Affairs in Hines, Ill., and colleagues conducted a national cross-sectional study involving 93,068 veterans aged 65 years and older with PTSD with or without concomitant dementia (11.1 percent with dementia). They examined trends in SGA prescribing in the population.

The researchers found that there was an annual decrease in SGA prescribing between 2004 and 2009, from 7 to 5.1 percent of elderly veterans with PTSD without dementia and from 13.2 to 8.9 percent in those with dementia. Over time, the findings consistently showed that veterans with PTSD and dementia versus those without dementia had at least twice the odds of being prescribed an SGA (odds ratios, 2.03 to 2.33).

"The findings were consistent over six years and strongly suggest that providers need to be educated about the complexities of prescribing SGAs to individuals with multiple medical and mental comorbidities," the authors write. "Future work should consider dissemination strategies to better understand why providers practice in this way."

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)